Funding

Delix Therapeutics

United States · Biotech

Delix Therapeutics develops neuroplastogen medicines for psychiatric and neurological disorders.

Visit delixtherapeutics.comFunding history

Product

Delix Therapeutics is a clinical-stage neuroscience company developing small-molecule medicines for psychiatric and neurological disorders. Its neuroplastogen platform is designed to promote changes in neural connections without the hallucinogenic effects associated with traditional psychedelics.

Its lead candidate, zalsupindole, has completed Phase Ib development in major depressive disorder. Delix is preparing a Phase II program while developing additional candidates for its broader pipeline.

Funding history

6 rounds · 6 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C$100MJohnson & Johnson Innovation – JJDC, Inc. — LeadSV Health Investors' Dementia Discovery Fund — LeadAdage Capital Management — ParticipantArtis Ventures — ParticipantBail Capital — ParticipantDolby Family Ventures — ParticipantHamilton Square Partners — ParticipantOMX Ventures — ParticipantRA Capital Management — ParticipantUC Investments — ParticipantVestal Point Capital — ParticipantYK Bioventures — Participant
Department of Defense research grant$825KU.S. Department of Defense — Participant
NIDA research grant$320KNational Institute on Drug Abuse — Participant
Convertible notes>$30MParticipants not disclosed
Credit facility option≤$10MComerica Bank — Participant
Series A$70MArtis Ventures — LeadOMX Ventures — LeadRA Capital Management — LeadApeiron — ParticipantBail Capital — ParticipantCasa Verde Capital — ParticipantDolby Family Ventures — ParticipantNegev Capital — ParticipantNoetic Fund — ParticipantOcama Partners — ParticipantPalo Santo — ParticipantPresight Capital — ParticipantPsyMed Ventures — ParticipantR2 — ParticipantRe.Mind Capital — ParticipantSaya Bio — ParticipantVertical Venture Partners — ParticipantWPSS — Participant

Investors

Johnson & Johnson Innovation – JJDC, Inc.Led Series CSV Health Investors' Dementia Discovery FundLed Series CAdage Capital ManagementJoined Series CArtis VenturesJoined Series C · Led Series ABail CapitalJoined Series C · Joined Series ADolby Family VenturesJoined Series C · Joined Series AHamilton Square PartnersJoined Series COMX VenturesJoined Series C · Led Series ARA Capital ManagementJoined Series C · Led Series AUC InvestmentsJoined Series CVestal Point CapitalJoined Series CYK BioventuresJoined Series CU.S. Department of DefenseJoined Department of Defense research grantNational Institute on Drug AbuseJoined NIDA research grantComerica BankJoined Credit facility optionApeironJoined Series ACasa Verde CapitalJoined Series ANegev CapitalJoined Series ANoetic FundJoined Series AOcama PartnersJoined Series APalo SantoJoined Series APresight CapitalJoined Series APsyMed VenturesJoined Series AR2Joined Series ARe.Mind CapitalJoined Series ASaya BioJoined Series AVertical Venture PartnersJoined Series AWPSSJoined Series A

Coverage

Nov 9, 2026Delix Therapeutics · Series CJun 4, 2024Delix Therapeutics · Department of Defense research grantDec 13, 2023Delix Therapeutics · NIDA research grant

Similar companies

Sunlit SeedlingsSunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.Undisclosed · Corporate investment
BiomatterBiomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.$18M · Series A
Orakl OncologyCombines patient-derived tumour organoids, clinical data and AI to help pharmaceutical companies develop cancer treatments.$34M · Series A
Sourcesdelixtherapeutics.com ↗delixtherapeutics.com ↗